In a bold step into the future of pharmaceutical innovation, Eli Lilly and Company has joined forces with NVIDIA Corporation to construct what the companies describe as the most powerful artificial-intelligence supercomputer ever built for the pharmaceutical industry.
The collaboration, announced October 28, 2025, aims to dramatically accelerate the discovery and development of new medicines by harnessing next-generation computing power and deep learning models.
Under the partnership’s terms, Lilly will host and operate the system within its own facilities, utilising more than 1,000 of NVIDIA’s latest generation Blackwell Ultra GPUs and a DGX SuperPOD architecture built specifically for large-scale life-science workflows.
The infrastructure is designed to support “millions of virtual experiments in parallel”, enabling the company’s scientists to explore vast chemical and biological spaces with far greater speed and scale than traditional approaches.
Lilly emphasises that the initiative is not just about speed but about intelligence: the supercomputer will power an “AI factory” in which models will not only be trained on decades of Lilly’s internal data, but deployed across functions including molecule design, biomarker discovery, clinical trial optimisation and manufacturing efficiency.
The companies say the installation is expected to be operational by January 2026, with the hardware being deployed in Lilly’s headquarters in Indianapolis and powered entirely by renewable electricity within its existing data-centre footprint.
NVIDIA’s Mission Control software will orchestrate the workloads across the DGX SuperPOD, enabling efficient scheduling, monitoring and orchestration of AI operations within a highly regulated pharmaceutical environment.
From an industry perspective, the move signals a broader shift in drug discovery: the combination of deep biology, high-performance computing and AI is increasingly seen as a key to reducing the decade-long timelines and multi-billion-dollar cost burdens typical of bringing a new medicine to market.
Lilly says the supercomputer will support its federated AI platform, TuneLab, which gives smaller biotech partners access to Lilly-trained models while preserving data privacy via federation.
Analysts note that while many pharmaceutical companies have begun deploying AI in pockets, few have committed to building in-house hardware of this scale.
Lilly’s strategy may provide a competitive edge by keeping its data and models within its own secure infrastructure rather than depending solely on cloud services.
Also Read: Apple Joins $4 Trillion Market-Cap Club After iPhone 17 Surge